SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Sugar Ray Robinson Synthetic CCD

PatientSugar Ray Robinson
Date of birth1963-05-03
IdentifiersMRN HR-BX003-SYN; SSN (made up) 000-03-9318
Document date2026-11-01
AuthorLangston Pryce-Okonjo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing care for memory loss and getting lost, with his care partner: cognitive testing, reversible causes, medicines, diabetes and blood pressure, driving and firearm safety. Concerns: He wants to know why he is forgetting and what can be done; He wants to keep his independence and keep working with the young fighters at the foundation; His care partner is worried about his driving and about managing alone. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route2024-03-01activeS
Glipizide 5 mg oral tablet, one tablet before breakfastOne tablet before breakfastOral route2025-01-15 to 2026-08-18completedS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2023-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2024-03-01activeS
Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counterOne capsule at bedtimeOral route2025-10-01 to 2026-07-07stoppedS
Donepezil 5 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route2026-08-18 to 2026-09-22completedS
Donepezil 10 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route2026-09-22 to 2026-10-01stoppedS
Donepezil 5 mg oral tablet, one tablet each morning with breakfastOne tablet each morning with breakfastOral route2026-10-01activeS

Procedures

ProcedureDatesStatusEvidence
MRI of the brain without contrast, with susceptibility-weighted imaging: moderate atrophy of both hippocampi, left more than right (medial temporal atrophy score 2 on each side), mild generalized atrophy, a few small white matter hyperintensities (Fazekas 1), six microbleeds at the gray-white junction of both frontal lobes and the right temporal lobe in a pattern seen after traumatic brain injury, no cortical superficial siderosis, no infarct, mass or hydrocephalus, and a cavum septi pellucidi, a finding common in boxers2026-07-21 to 2026-07-21completedS
Pure tone audiometry: mild to moderate bilateral high-frequency sensorineural hearing loss, symmetric; speech understanding good in quiet, reduced in noise2026-07-21 to 2026-07-21completedS
Amyloid PET with florbetapir: positive, with widespread cortical tracer uptake (about 90 Centiloids), confirming Alzheimer's disease pathology2026-08-04 to 2026-08-04completedS
Twelve-lead ECG before donepezil: sinus rhythm at 70 per minute, PR interval 172 ms, QTc 414 ms, no conduction block2026-08-18 to 2026-08-18completedS
Fitting of hearing aids for both ears by the audiologist, with teaching for him and his care partner2026-09-01 to 2026-09-01completedS
Advance care planning conversation, about 30 minutes, with him and his care partner; his capacity to name a health care agent and state his values was assessed and present2026-09-08 to 2026-09-08completedS
Twelve-lead ECG: sinus bradycardia at 56 per minute, PR interval 180 ms, QTc 420 ms, no heart block2026-10-01 to 2026-10-01completedS

Immunizations

DateVaccineStatusEvidence
2026-09-08Influenza vaccine for the coming seasoncompletedS
2026-09-08Pneumococcal conjugate vaccine (PCV20), recommended for all adults aged 50 and oldercompletedS
2026-09-08Recombinant zoster vaccine, first of two dosescompletedS
2026-09-22Tdap vaccine, deferred from the preventive visit at his requestcompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1940 to 1965About 200 professional bouts over 25 years of boxing, after an amateur career: long exposure to repetitive head impacts; no source read records a knockout count with loss of consciousness or a brain injury diagnosisD (CLM-0002, CLM-0004)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He wants to know why he is forgetting and what can be doneactiveS
He wants to keep his independence and keep working with the young fighters at the foundationactiveS
His care partner is worried about his driving and about managing aloneactiveS

Assessment

Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.4 on 2026-07-07; Hemoglobin [Mass/volume] in Blood 14.1 on 2026-07-07; Platelets [#/volume] in Blood by Automated count 231 on 2026-07-07; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-10-01; Potassium [Moles/volume] in Serum or Plasma 4.4 on 2026-10-27; Creatinine [Mass/volume] in Serum or Plasma 1 on 2026-10-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 85 on 2026-10-27; Glucose [Mass/volume] in Serum or Plasma 112 on 2026-10-01; Hemoglobin A1c/Hemoglobin.total in Blood 6.9 on 2026-09-22; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 352 on 2026-07-07; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-07-07; Albumin/Creatinine [Mass Ratio] in Urine 14 on 2026-07-07; Total score [MoCA] 18 on 2026-07-07; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-27; Mini-Mental State Examination [MMSE] 22 on 2026-07-21; Clinical Dementia Rating scale [CDR] 1 on 2026-07-21; Cholesterol [Mass/volume] in Serum or Plasma 154 on 2026-09-08; Cholesterol in HDL [Mass/volume] in Serum or Plasma 49 on 2026-09-08; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 79 on 2026-09-08; Triglyceride [Mass/volume] in Serum or Plasma 128 on 2026-09-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-08 [S]

Strengths and supports: Strengths and supports: discipline and daily exercise, pride in his career, a warm and sociable manner, his care partner, friends from boxing, and the young people at the foundation [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be foundresolvedconfirmed R41.3S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, consideredactiveconfirmed G30.0S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease.
Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptomsactiveconfirmed F02.A0S — Synthetic stage at diagnosis.
Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylureaactiveconfirmed E11.9S — Synthetic modern diabetes anchored to his documented diabetes.
Hypertension, controlled on lisinoprilactiveconfirmed I10S — Synthetic modern hypertension anchored to the single press report.
Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometryactiveconfirmed H90.3S — Synthetic finding checked as a modifiable contributor to cognitive difficulty.
Nausea, loose stools, dizziness on standing and a slow pulse (56) nine days after donepezil was raised to 10 mg, with mild dehydration (creatinine 1.2 mg/dL); resolved after returning to 5 mg in the morning and two days of sick-day rulesresolvedconfirmed R11.0S — Synthetic adverse effect of a cholinesterase inhibitor; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-07Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
2026-07-07Hemoglobin [Mass/volume] in Blood14.1g/dL13.5-17.5 g/dLNormalS
2026-07-07Platelets [#/volume] in Blood by Automated count23110*3/uL150-400 10*3/uLNormalS
2026-07-07Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-07-07Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-07-07Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.74-1.35 mg/dLNormalS
2026-07-07Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-07Glucose [Mass/volume] in Serum or Plasma126mg/dL70-140 mg/dLNormalS
2026-07-07Hemoglobin A1c/Hemoglobin.total in Blood6.4%<=5.6%HighS
2026-07-07Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma352pg/mL232-1245 pg/mLNormalS
2026-07-07Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
2026-07-07Albumin/Creatinine [Mass Ratio] in Urine14mg/g<=29 mg/gNormalS
2026-07-07Total score [MoCA]18{score}S
2026-07-07Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-07-21Mini-Mental State Examination [MMSE]22{score}S
2026-07-21Clinical Dementia Rating scale [CDR]1{score}S
2026-09-22Hemoglobin A1c/Hemoglobin.total in Blood6.9%<=5.6%HighS
2026-10-01Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-10-01Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-10-01Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.74-1.35 mg/dLNormalS
2026-10-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M68mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-01Glucose [Mass/volume] in Serum or Plasma112mg/dL70-140 mg/dLNormalS
2026-10-27Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-10-27Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.74-1.35 mg/dLNormalS
2026-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-09-08Cholesterol [Mass/volume] in Serum or Plasma154mg/dL<=199 mg/dLNormalS
2026-09-08Cholesterol in HDL [Mass/volume] in Serum or Plasma49mg/dL>=40 mg/dLNormalS
2026-09-08Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation79mg/dL<=99 mg/dLNormalS
2026-09-08Triglyceride [Mass/volume] in Serum or Plasma128mg/dL<=149 mg/dLNormalS
2026-09-08Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-07-07Body height180cmS
2026-07-07Body weight77kgS
2026-07-07Body mass index (BMI) [Ratio]23.8kg/m2S
2026-07-07Systolic blood pressure132mm[Hg]S
2026-07-07Diastolic blood pressure80mm[Hg]S
2026-07-07Heart rate72/minS
2026-07-07Respiratory rate14/minS
2026-07-07Body temperature36.7CelS
2026-07-07Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-07-21Body height180cmS
2026-07-21Body weight76.8kgS
2026-07-21Body mass index (BMI) [Ratio]23.7kg/m2S
2026-07-21Systolic blood pressure128mm[Hg]S
2026-07-21Diastolic blood pressure78mm[Hg]S
2026-07-21Heart rate70/minS
2026-07-21Respiratory rate14/minS
2026-07-21Body temperature36.6CelS
2026-07-21Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-18Body height180cmS
2026-08-18Body weight76.6kgS
2026-08-18Body mass index (BMI) [Ratio]23.6kg/m2S
2026-08-18Systolic blood pressure126mm[Hg]S
2026-08-18Diastolic blood pressure78mm[Hg]S
2026-08-18Heart rate70/minS
2026-08-18Respiratory rate14/minS
2026-08-18Body temperature36.6CelS
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-22Body height180cmS
2026-09-22Body weight76.2kgS
2026-09-22Body mass index (BMI) [Ratio]23.5kg/m2S
2026-09-22Systolic blood pressure128mm[Hg]S
2026-09-22Diastolic blood pressure76mm[Hg]S
2026-09-22Heart rate64/minS
2026-09-22Respiratory rate14/minS
2026-09-22Body temperature36.6CelS
2026-09-22Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-27Body height180cmS
2026-10-27Body weight75.8kgS
2026-10-27Body mass index (BMI) [Ratio]23.4kg/m2S
2026-10-27Systolic blood pressure126mm[Hg]S
2026-10-27Diastolic blood pressure76mm[Hg]S
2026-10-27Heart rate66/minS
2026-10-27Respiratory rate14/minS
2026-10-27Body temperature36.5CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-08Body height180cmS
2026-09-08Body weight76.4kgS
2026-09-08Body mass index (BMI) [Ratio]23.6kg/m2S
2026-09-08Systolic blood pressure126mm[Hg]S
2026-09-08Diastolic blood pressure76mm[Hg]S
2026-09-08Heart rate68/minS
2026-09-08Respiratory rate14/minS
2026-09-08Body temperature36.6CelS
2026-09-08Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-01Body height180cmS
2026-10-01Body weight74.6kgS
2026-10-01Body mass index (BMI) [Ratio]23kg/m2S
2026-10-01Systolic blood pressure118mm[Hg]S
2026-10-01Diastolic blood pressure70mm[Hg]S
2026-10-01Heart rate56/minS
2026-10-01Respiratory rate16/minS
2026-10-01Body temperature36.8CelS
2026-10-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-07-07Establishing care for memory loss and getting lost, with his care partner: cognitive testing, reversible causes, medicines, diabetes and blood pressure, driving and firearm safetyfinishedS
2026-07-21Two-week review, seen the same day by cognitive neurology: brain MRI, hearing test, staging, Alzheimer's disease against traumatic encephalopathy syndrome, and anti-amyloid eligibilityfinishedS
2026-08-18Six-week review: amyloid PET result, the diagnosis and the plan, with diabetes, driving, firearm and caregiver supportfinishedS
2026-09-22Eleven-week review: donepezil dose, diabetes, hearing aids and day programfinishedS
2026-10-27Sixteen-week review: medicines, kidneys, mood, caregiver strain and the planfinishedS
2026-09-08Periodic adult preventive visitfinishedS
2026-10-01Same-day sick visit for nausea and dizziness on donepezilfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Dementia work-up under the Alzheimer's Association guideline: history from him and his care partner, MoCA, function, depression screening, first-tier blood tests (blood count, metabolic panel, B12, TSH), a review of medicines for anticholinergic and sedating drugs, a sleep apnea screen, and brain MRIcompletedGL-ALZ-2024, GL-ALZ-PC-2024, GL-CMID-2026S
Cognitive neurology consultation at the memory clinic to stage the dementia, weigh Alzheimer's disease against traumatic encephalopathy syndrome and vascular disease, choose biomarker testing, and decide anti-amyloid eligibilitycompletedGL-ALZ-2024, GL-TES-2021, GL-AUR-LEC-2023, GL-AUR-DON-2025S
Stop diphenhydramine, a strongly anticholinergic sleep aid; sleep habits and morning light insteadcompletedGL-BEERS-2023S
Driving: no driving until the evaluation is complete, with his care partner driving; firearm: unloaded and locked, with the key held by his care partner, until a decision with himcompletedGL-AAN-DRIVING-2010, GL-ALZ-2024S
Amyloid PET to confirm Alzheimer's disease pathology; APOE genotyping not needed because he is not a candidate for anti-amyloid therapy, and offered only with counselingcompletedGL-ALZ-2024, GL-AUR-LEC-2023, GL-AUR-DON-2025S
Donepezil 5 mg at bedtime with a baseline ECG and pulse checks, raised to 10 mg after four to six weeks if tolerated; taken in the morning if dreams are vividcompletedGL-ALZ-2024, GL-CMID-2026S
Diabetes deintensified under the ADA Standards for older adults: stop glipizide, continue metformin, hemoglobin A1c goal under 8.0%, sick-day rules (hold metformin when not eating or drinking), and B12 checked periodicallycompletedGL-ADA-OLDER-2026, GL-CMID-2026S
Blood pressure under 130/80 mmHg on lisinopril, with potassium and creatinine checkscompletedGL-ADA-OLDER-2026, GL-CMID-2026S
Hearing aids for both ears, fitted by the audiologistcompletedGL-ALZ-2024S
Stop driving after the diagnosis (CDR 1 and getting lost), with transport planned; the handgun removed from the homecompletedGL-AAN-DRIVING-2010, GL-ALZ-2024S
Caregiver support: education, the Alzheimer's Association 24/7 Helpline, an adult day program for respite, a caregiver burden check, and the Medicare GUIDE dementia care model once he has MedicarecompletedGL-GUIDE, GL-ALZ-2024S
Advance care planning while he can take part fully: a health care agent and his values, at the preventive visitcompletedGL-ALZ-2024S
Exercise, social activity and diabetes and blood pressure control as the brain-health measures with the most supportcompletedGL-ALZ-2024, GL-ADA-OLDER-2026S

Goals

GoalTargetStatusOutcomeProvenance
Find the cause of the memory loss and explain it to him in a way he can take in2026-08-18completedAlzheimer's disease confirmed by amyloid PET; disclosed with his care partner present, at his request, with written notesS
No hypoglycemia, with hemoglobin A1c under 8.0%2026-10-27completedGlipizide stopped after one reading of 68 mg/dL; no low readings since; A1c 6.4 to 6.9%S
Stay safe: no driving and no firearm in the home2026-08-18completedHe stopped driving and the handgun was removed from the homeS
Keep his days full and give his care partner regular breaks2026-10-27completedAdult day program two days a week; walks and the foundation gym on other days; Alzheimer's Association helplineS

Functional Status

Mental Status